Diagnostic and Treatment Pathways for Locally Advanced and Metastatic Prostate Cancer

Dear Colleagues,

Prostate cancer is the second leading cause of cancer-related death globally. Thus, patients with locally advanced or metastatic stages of cancer have been the focus of recent research. Emerging insights and an increased understanding of prostate cancer tumor biology have demonstrated that the concept of ‘one size fits all’ does not account for locally advanced or metastatic prostate cancer patients.

In locally advanced prostate cancer, precise staging and consequently, allocating the patient the most beneficial treatment, represents an ongoing field of interest. In particular, selecting the most appropriate multimodal treatment according to the patient’s specific risk level is of utmost importance to establish a balance between adequate cancer control and preventing overtreatment and its associated side effects.

For metastatic prostate cancer patients, treatment decision is becoming increasingly sophisticated and can be tailored to both hormone-sensitive and castration-resistant diseases. Substantial efforts in the recent past have gone towards unscrambling sequences and the most efficient combination of systemic-acting treatment regimens (including androgen deprivation, novel secondary hormonal therapy, chemotherapy); in addition, surgical and radiation treatments result in the most beneficial survival outcome. Moreover, the application of of PARP inhibitors in castration-resistant patients has further expanded the therapeutic armamentarium. 

For this Special Issue, we are inviting research which focuses on diagnostic and treatment pathways for locally advanced and metastatic prostate cancer patients. Both original articles and reviewers are welcome. Potential and exciting research areas may include (but are not limited to) the following: prostate cancer, (oligo-)metastatic disease, chemotherapy, hormonal therapy, targeted therapy, metastasis-directed treatment, PARP, and sequencing.

We look forward to receiving your submission.

Prof. Dr. Felix K.H. Chun
Prof. Dr. Philipp Mandel
Dr. Benedikt Hoeh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• prostate cancer
• (oligo-)metastatic disease
• chemotherapy
• hormonal therapy
• targeted therapy
• metastasis-directed treatment
• PARP
• sequencing